GlassScriptPhysician profile
Ben Terrany
NPI 1578528592
$9,244.68
in general payments reported to CMS, 2019-2025
36 companies · $2,318 in 2025
The $2,318 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $423 · 2021: $372 · 2022: $902 · 2023: $1,156 · 2024: $2,817 · 2025: $2,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,251 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,250.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.07 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,001.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $958.65 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $878.01 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $846.88 | 2019-2025 | |
| Intra-Sana Laboratories | $594.04 | 2024-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Phathom Pharmaceuticals, INC. | $535.48 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $392.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $336.58 | 2022-2023 | Endoflip |
| Daiichi Sankyo INC. | $271.94 | 2019-2024 | Injectafer |
| Genzyme Corporation | $199.84 | 2022-2025 | |
| Celgene Corporation | $196.47 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $165.10 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $147.33 | 2019 | |
| Qol Medical, LLC | $135.79 | 2024-2025 | Sucraid, Sucraid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $133.66 | 2023-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $126.63 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2023 | Andexxa |
| Janssen Pharmaceuticals, INC | $124.97 | 2020 | |
| Janssen Scientific Affairs, LLC | $119.69 | 2022 | |
| Ferring Pharmaceuticals INC. | $84.19 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $70.18 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $66.38 | 2019-2021 | |
| Amgen INC. | $60.35 | 2020-2025 | Uplizna |
| Intercept Pharmaceuticals, INC. | $55.00 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $52.48 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $42.87 | 2019 | |
| Celltrion USA INC. | $34.15 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $32.37 | 2020-2024 | |
| Sandoz INC. | $25.35 | 2025 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $18.98 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $17.65 | 2024 | |
| Fresenius Kabi USA, LLC | $16.39 | 2023 | Idacio |
| Braintree Laboratories, INC. | $15.82 | 2023 | Sutab, Suflave |
| Endogastric Solutions, INC | $15.44 | 2023 | Esophyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Terrany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.